Systemic administration of hypocretin-1 reduces cataplexy and normalizes sleep and waking durations in narcoleptic dogs.
|Title||Systemic administration of hypocretin-1 reduces cataplexy and normalizes sleep and waking durations in narcoleptic dogs.|
|Publication Type||Journal Article|
|Year of Publication||2000|
|Authors||John J, Wu MF, Siegel JM|
|Journal||Sleep Res Online|
|Keywords||Animals, Behavior, Animal, Carrier Proteins, Cataplexy, Circadian Rhythm, Disease Models, Animal, Dogs, Dose-Response Relationship, Drug, Electroencephalography, Electromyography, Electrooculography, Female, Injections, Intravenous, Intracellular Signaling Peptides and Proteins, Male, Motor Activity, Narcolepsy, Neuropeptides, Orexins, Sleep, Sleep Stages, Treatment Outcome, Wakefulness|
Recent work has implicated the hypocretin (orexin) system in the genesis of narcolepsy. In the current study we demonstrate that systemically administered hypocretin-1 (Hcrt-1) produces an increase in activity level, longer waking periods, a decrease in REM sleep without change in nonREM sleep, reduced sleep fragmentation and a dose dependent reduction in cataplexy in canine narcoleptics. Repeated administration of single daily doses of Hcrt-1 led to consolidation of waking and sleep periods and to a complete loss of cataplexy for periods of three or more days after treatment in animals that were never asymptomatic under control conditions. Systemic administration of Hcrt-1 may be an effective treatment for narcolepsy.
|Alternate Journal||Sleep Res Online|
|Grant List||HL41370 / HL / NHLBI NIH HHS / United States |
HL60296 / HL / NHLBI NIH HHS / United States
NS14610 / NS / NINDS NIH HHS / United States